- Oops!Something went wrong.Please try again later.
Ryan Detrick, chief market strategist at LPL Financial, joins Yahoo Finance to discuss outlook on the market and upcoming earnings season.
Ryan Detrick, chief market strategist at LPL Financial, joins Yahoo Finance to discuss outlook on the market and upcoming earnings season.
Military cooperation in the European Union will get a boost as the 27 nation bloc is admitting for the first time outside partners such as the United States, Canada and Norway into one of its projects, Germany said on Thursday. "It will be a quantum leap in terms of concrete cooperation," German Defence Minister Annegret Kramp-Karrenbauer said ahead of the first in-person meeting with her EU counterparts in over a year in Brussels. The EU project on military mobility is designed to facilitate the movement of troops across Europe, something NATO deems as crucial in the event of a conflict with Russia.
(Bloomberg) -- ArcelorMittal SA reported its highest quarterly profit in a decade as steel prices soared amid a commodities boom that’s touched everything from copper to corn.The biggest steelmaker outside China said it now expects steel demand this year -- a key barometer for global economic growth -- to be at or above the upper range of its February forecast. It projected an increase in demand of 4.5% to 5.5%, following a contraction in 2020 during the pandemic.Aditya Mittal took the helm at ArcelorMittal from his father this year as rebounding demand from the manufacturing and construction industries collides with tight supply. The resulting boom has pushed benchmark European steel prices to the highest on record, as the reopening of economies sparks a surge across commodities markets from iron ore to lumber.“As prices have continued to increase I would expect the second quarter to be even stronger,” said Ingo Schachel at Commerzbank AG. “I like the consistently good performance in all steel segments.”First-quarter earnings before interest, taxes, depreciation and amortization were $3.24 billion, ArcelorMittal said Thursday in a statement. That surpassed analysts’ estimates.“The first quarter of this year has been our strongest in a decade,” said incoming Chief Executive Officer Aditya Mittal. “While this is naturally a very welcome development following a highly challenging 2020, we are mindful that Covid continues to be a health challenge across the world especially in developing economies.”ArcelorMittal fell 0.9% in Amsterdam trading, after gaining 4.9% on Wednesday. The shares have surged 168% over the past 12 months.Steel producers in Europe and America have suffered for years from low prices caused by global overcapacity. That was initially compounded by the onset of the pandemic, before a dramatic turnaround over the past year.Futures in China, by far the biggest producer, have smashed records -- even outpacing gains in key ingredient iron ore -- as the government took measures to curb output. That’s supercharged rallies of benchmark prices in Europe and America, where mills were already running at maximum capacity as they try to meet unexpectedly high demand.Steel and iron ore futures resumed trading on a strong foot on Thursday as investors in China returned after a public holiday. Expectations are building that iron ore prices can reach $200 a ton, while rebar and hot-rolled coil futures in Shanghai marched to new heights, as demand continues to be robust from Asia to North America.ArcelorMittal and other western steelmakers could further benefit should China’s output decline on the back of a crackdown on emissions. Keeping prices higher for longer could also help fund decarbonization initiatives in the steel industry.Other highlights:First-quarter Ebitda from iron ore mining more than tripled to $1.07 billion from year earlier.Gross debt declined to $11.4 billion at end of first quarter, while net debt dropped to $5.9 billion.Company to pay 30 cents a share dividend in June as part of plan to return $570 million to shareholders.(Updates with shares in seventh paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The Queensland Reds' rivalry with the ACT Brumbies has breathed new life into Australian rugby this year and raised hopes for a classic final in Brisbane on Saturday. The teams meet in their second successive Super Rugby AU decider, with the Brumbies bidding for back-to-back titles after downing Brad Thorn's Reds 28-23 last year in front of a small, socially-distanced crowd at Canberra Stadium. The Reds, however, will feel their time has come, having edged the Brumbies in two come-from-behind thrillers during the regular season.
The book deal comes after the Sussexes signed a lucrative contract with Netflix and Spotify.
(Bloomberg) -- U.S. support for a waiver of intellectual-property protections for Covid-19 vaccines heads to the World Trade Organization for potentially thorny talks over sharing the proprietary know-how needed to boost global supplies of the life-saving shots.“In terms of how soon the WTO can deliver -- that literally depends on the WTO members, collectively, being able to deliver,” U.S. Trade Representative Katherine Tai said in an interview Wednesday. “I am the first one to admit that what we are leaning into is a process that is not going to be easy.”On Thursday the European Union signaled a willingness to take part in the negotiations, as shares of European vaccine makers tumbled.“The EU is ready to discuss any proposal that addresses the crisis in an effective and pragmatic manner,” European Commission President Ursula von der Leyen told a virtual conference in Florence, Italy. “And that’s why we are ready to discuss how the U.S. proposal for a waiver on IP protection for Covid vaccines could help achieve that objective.”The WTO’s General Council meets again on Thursday, though any final agreement that drugmakers are likely to oppose may take weeks to hammer out. Tai added that she sees momentum from WTO Director-General Ngozi Okonjo-Iweala “to take this opportunity and see what is the WTO capable of.”In a statement, Okonjo-Iweala called it the “moral and economic issue of our time.”The Biden administration will encourage other countries to join its position, Tai said. “We are for the waiver at the WTO, we are for what the proponents of the waiver are trying to accomplish, which is better access, more manufacturing capability, more shots in arms,” she said.Vaccine makers’ shares fell in Europe. The depositary receipts of Pfizer Inc.’s partner BioNTech SE dropped as much as 19% in Germany. Together, the companies sell the messenger RNA shot that was one of the first to win regulatory endorsement. CureVac NV of Germany, which is developing another mRNA vaccine, fell as much as 16%.The waiver has been opposed by drugmakers, who say the plan is ineffective. They argue that few countries have the capacity to produce more vaccines even if they knew the formulas. Also, there’s limited global supply of the materials needed, and building new factories with the necessary technology to produce the vaccines could take years, they say.“This change in longstanding American policy will not save lives,” said Stephen Ubl, the president and CEO of PhRMA, the biopharma industry’s lobbying group. “This decision does nothing to address the real challenges to getting more shots in arms, including last-mile distribution and limited availability of raw materials. These are the real challenges we face that this empty promise ignores.”India and South Africa, two nations struggling to contain fresh outbreaks of Covid-19, have been urging WTO members to temporarily suspend rules on IP rights, arguing that it would be the most efficient and equitable way to address vaccine shortages in poor countries.”We will be exercising our convening power at the WTO to bring members together to work towards resolving the different viewpoints to bridge the gap so that the WTO can be relevant, the WTO can be a force for good,” Tai said.Other HoldoutsThe U.S. wasn’t the only country with reservations about the waiver. The EU, U.K., Japan, Switzerland, Brazil and Norway have also resisted the push. However, supporters of the waiver argue that U.S. leadership on the issue could help sway other holdouts. The timing for approval of the waiver depends on how soon member states can find agreement.“Given what is at stake, this is the best chance for the WTO to be able to come together to deliver something that is going to help people and make a difference,” Tai said.As the U.S. inoculations advanced and outbreaks diminished in recent weeks, the White House came under pressure from progressive Democrats and public-health advocates to take a stance while India in particular suffers from surging deaths and infections.As inter-agency discussions were ongoing, Tai also met with top executives of vaccine-producing companies and held calls with members of Congress and other stakeholders in civil society and public health.At a WTO meeting on Wednesday, India and South Africa agreed to revise their proposal, first introduced in October, to present to members for a meeting tentatively scheduled for the second half of May.In April, Tai called on the pharmaceutical industry to make sacrifices.“The desperate needs that our people face in the current pandemic provide these companies with an opportunity to be the heroes they claim to be -- and can be,” she said at a virtual conference at the WTO. “As governments and leaders of international institutions, the highest standards of courage and sacrifice are demanded of us in times of crisis. The same needs to be demanded of industry.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The group said it is set to complete more homes this year than first predicted, at between 16,000 and 16,250.
(Bloomberg) -- Aston Martin Lagonda Global Holdings Plc reported better-than-expected sales for the first quarter as the British luxury-car maker gets a significant boost from its first-ever SUV.Revenue soared 153% to 244.4 million pounds ($340 million), beating analysts’ average estimate for 196.7 million pounds. The DBX sport utility vehicle accounted for 55% of the vehicles sold to dealers in the first three months of the year.Aston Martin racked up significant losses after going public in 2018 and has spent the last year restructuring itself after a rescue by Canadian billionaire Lawrence Stroll. The 61-year-old fashion mogul has injected much-needed cash and forged closer ties with Daimler AG’s Mercedes-Benz to ensure the company survives tumultuous times for the auto industry.Soon after taking over as chairman last year, Stroll shook up Aston Martin’s management and brought in Tobias Moers, who previously led Daimler AG’s Mercedes-AMG performance division, as chief executive officer. He also set a target to earn 500 million pounds on 2 billion pounds of revenue by 2025.“On both our short and medium targets, we remain more confident every day,” Stroll said in a phone interview Thursday. “It’s the first true, clean quarter that we have had as the new management team running the business and very indicative of what’s to come.”DBX DerivativesAston Martin plans to expand its portfolio of SUVs as well as introduce hybrid and electric powertrains. Moers said the first derivative model on the DBX platform will launch in the third quarter, with another variant planned for next year.“These are strong results, and while this should have been expected by the market we believe this should support shares as the management turnaround plan continues to gather traction,” Angus Tweedie, an analyst at Citigroup, wrote in a note to clients.Aston Martin’s shares rose as much as 4.7% and were up 2.6% at 8:50 a.m. in London. The stock has almost doubled in the past year.Debut HybridIn October, Aston Martin reached an agreement for Mercedes to supply hybrid and electric components to the U.K. company, building on an engine tie-up that started in 2013. Mercedes will boost its stake in the carmaker from 2.6% to as much as 20% over three years. Aston Martin plans to introduce its first plug-in hybrid model in 2023, Moers said.Deliveries of the 158,000-pound DBX began midway through last year. Average vehicle selling prices improved significantly in the first quarter, driven by strong demand from China and de-stocking of older models. The company expects as much as 40% of volume to come from the U.S. and China in the future, Moers said.Aston Martin will begin shipping the new Valkyrie hypercar in the second half of the year.(Updates with comments from chairman and CEO from the fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Follow live updates below
during the forecast period. Growing adoption of AR and VR devices in various applications, increasing demand for OLED displays in AR and VR devices, growing adoption of AR and VR HMDs in different industries, and adoption of AR and VR devices in gaming industry are the key driving factors for the AR and VR display market.New York, May 06, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "AR and VR Display Market with COVID-19 Impact Analysis by Device Type, Technology, Display Technology, Application And Geography - Global Forecast to 2026" - https://www.reportlinker.com/p05828515/?utm_source=GNW However, development of widescreen alternatives and limited availability of relevant content hampering the growth of the market.HMDs to witness a higher CAGR during the forecast period.The use of AR HMDs for enterprise and healthcare applications will be the major factor driving the growth of the market in the next 5 years.AR HMDs are used in different applications, including consumer, commercial, enterprise, aerospace & defense, automotive, and healthcare.The use of AR HMDs in retail would drive the market growth for AR HMDs for commercial applications.The increasing number of local manufacturers and the growing adoption of VR HMDs in APAC are among the major factors for the high estimated growth of VR HMDs in APAC.Local vendors have been promoting their products at a lower price than the tech giants that have entered this space with high-end products. Though per unit cost of products is low in this region, the high sales volume of these products in the region will lead APAC to be the major shareholder of the market during the forecast period.Consumer application to account the largest share of the VR display market during the forecast period.The consumer application held the largest size of the VR display market in 2020.The introduction of VR in consumer technologies has led to the launch of many innovative products in the market.Moreover, continuous decline in the cost of VR devices, software developments, and relevant content developments are driving the market for VR.The growing use of VR HMDs for gaming will propel the market for consumer applications.Virtual reality technology offers remarkable visual effects when used in gaming and sports broadcasts.The demand for head-mounted displays is high in consumer applications because of their use in gaming and sports & entertainment.Samsung Gear VR, Oculus Rift, PlayStation VR, and HTC Vive are among the popular HMDs that are used in various consumer applications.APAC to account the largest share during 2021–2026.The VR display market growth in APAC is driven by countries such as China, Japan, and South Korea due to the presence of major display manufacturers, growing consumer demand, and decreasing price of VR devices.Owing to the presence of a number of display panel manufacturers in the region, the adoption of the latest display technologies is high in APAC.The use of VR displays in APAC is expected to grow in healthcare, commercial, and enterprise verticals. The commercial and enterprise verticals in APAC have adopted these displays at large owing to the easy availability of VR devices in the region.In-depth interviews have been conducted with chief executive officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the AR and VR display marketplace. • By Company Type: Tier 1 - 25%, Tier 2 – 40%, and Tier 3 - 35%• By Designation: C-Level Executives - 75% and Managers - 25%• By Region: North America - 40%, Europe - 23%, APAC - 26%, and RoW 11%The AR and VR display market comprises major players such as Samsung Electronics (South Korea), Sony (Japan), LG Display (South Korea), eMagin Corporation (US), Kopin Corporation (US), AU Optronics (Taiwan), Japan Display (Japan), Barco (Belgium), BOE Technology (China), and Syndiant (US). The study includes an in-depth competitive analysis of these key players in the AR and VR display market, with their company profiles, recent developments, and key market strategies.Research CoverageThe report defines, describes, and forecasts the AR and VR display market based on technology, device type, display technology, application, and region.It provides detailed information regarding factors such as drivers, restraints, opportunities, and challenges influencing the growth of the AR and VR display market.It also analyzes competitive developments such as product launches, acquisitions, expansions, contracts, partnerships, and developments carried out by the key players to grow in the market.Key Benefits of Buying the ReportThe report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AR and VR display market and the subsegments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.Read the full report: https://www.reportlinker.com/p05828515/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
The value of Barratt Developments’ forward order book has risen to £3.4 billion, as the FTSE 100 firm benefits from the UK housing boom. Chief executive David Thomas also said in the year to June, Barratt expects to complete sales on 16000 to 16250 homes. The housebuilder has benefited from a number of measures including a stamp duty holiday enticing buyers and numerous people reassessing their housing needs during Covid-19 lockdowns.
Madonna and Levi's have paid tribute to "kind" and "sweet" model and singer Nick Kamen, "the man who made the 501 even more iconic". Kamen, who was best known for stripping off in a launderette to wash his jeans in the famous 1980s Levi's advert, also had a music career and was considered a protege of the Queen of Pop. Paying tribute on Twitter following his death at the age of 59, Madonna described the star as "such a kind and sweet human" and said "it breaks my heart to know you are gone".
Sterling is likely to be in focus too, with the Bank of England’s meeting later today.
U.S. Secretary of State Antony Blinken said the West had to be very careful about the exact nature of Chinese investment in Western economies and think very carefully about investments in strategic assets. China's spectacular economic and military rise over the past 40 years is among the most significant geopolitical events of recent history, alongside the 1991 fall of the Soviet Union that ended the Cold War. The West has struggled to come up with an agreed policy on China and has flipflopped over the years from seeing China as a lucrative source of investment - for example in U.S. government bonds - to seeing China as a threat to global stability and avoiding its 5G technology.
Chinese netizens have urged authorities to crack down on the illegal practice of delivering animals via "blind boxes" after local media reported that 160 puppies and kittens had been rescued from a warehouse in the city of Chengdu on Monday. The animals were held in boxes and disguised as regular express deliveries by local merchants selling pets online, CCTV and other state media outlets reported. They were ready to be dispatched to locations throughout China, including Shenzhen more than 1,000 miles (1,700 km) away, until animal welfare volunteers intervened, the reports said.
The United States threw its weight behind a waiver on patent protections for Covid-19 vaccines as India Thursday posted record deaths and infections from a catastrophic wave swamping the country.
Esme said she made the necklace herself as a way of "expressing myself by being creative".
TORM plc (“TORM” or the “Company”) (ticker: TRMD A on Nasdaq in Copenhagen and TRMD on Nasdaq in New York) will release its financial results for the first quarter of 2021 on Wednesday, 12 May 2021. The Company’s results will be presented at a conference call at 9:00 am Eastern Time / 3:00 pm Central European Time. If you wish to participate in the call, please dial +45 3272 0417 (or +1 (646) 741 3167 for US connections) at least ten minutes prior to the start of the call to ensure connection and use 4286408 as conference ID. The presentation can be downloaded from https://investors.torm.com. There will be a simultaneous live webcast via TORM’s website https://investors.torm.com. Participants should register on the website approximately ten minutes prior to the start of the webcast. A telephonic replay of the conference call will be available until 26 May 2021 by dialing +44 (0) 333 3009785 (or +1 (866) 331 1332 for US connections) and using 4286408 as your access code. CONTACT TORM plcMorten Agdrup, IR, tel.: +45 3917 9249Birchin Court, 20 Birchin Lane London, EC3V 9DU, United Kingdom Tel.: +44 203 713 4560 www.torm.com ABOUT TORM TORM is one of the world’s leading carriers of refined oil products. The Company operates a fleet of approximately 80 modern vessels with a strong commitment to safety, environmental responsibility and customer service. TORM was founded in 1889. The Company conducts business worldwide. TORM’s shares are listed on Nasdaq in Copenhagen and on Nasdaq in New York (ticker: TRMD A and TRMD). For further information, please visit www.torm.com. SAFE HARBOR STATEMENTS AS TO THE FUTUREMatters discussed in this release may constitute forward-looking statements. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and statements other than statements of historical facts. The words “believe,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions generally identify forward-looking statements. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond our control, the Company cannot guarantee that it will achieve or accomplish these expectations, beliefs or projections. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of the world economy and currencies, general market conditions, including fluctuations in charter hire rates and vessel values, the duration and severity of the COVID-19, including its impact on the demand for petroleum products and the seaborne transportation thereof, the operations of our customers and our business in general, changes in demand for “ton-miles” of oil carried by oil tankers and changes in demand for tanker vessel capacity, the effect of changes in OPEC’s petroleum production levels and worldwide oil consumption and storage, changes in demand that may affect attitudes of time charterers to scheduled and unscheduled dry-docking, changes in TORM’s operating expenses, including bunker prices, dry-docking and insurance costs, changes in the regulation of shipping operations, including actions taken by regulatory authorities, potential liability from pending or future litigation, domestic and international political conditions, potential disruption of shipping routes due to accidents, political events including “trade wars,” or acts by terrorists. In light of these risks and uncertainties, you should not place undue reliance on forward-looking statements contained in this release because they are statements about events that are not certain to occur as described or at all. These forward-looking statements are not guarantees of our future performance, and actual results and future developments may vary materially from those projected in the forward-looking statements. Except to the extent required by applicable law or regulation, the Company undertakes no obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. Attachment 14-2021 - TORM plc to announce Q1 2021 results - US
A police motorcycle was set on fire by demonstrators in the Colombian capital of Bogota, as protests sparked by now-shelved tax reforms continued on May 5.Video by Alexander Bare shows protesters cheering after as the motorcycle burns. Bare told Storyful that the incident happened after security forces cleared protesters from the Plaza de Bolivar.Violent scenes have accompanied protests in Colombia against planned post-pandemic tax reforms that began on April 28. The reforms have since been shelved. Credit: Alexander Bare via Storyful
Globally Pharmaceutical markets are showing rapid growth and in coming years expected to evolve further in the field of research and development, manufacturing, and formulation due to rise in population, increase in chronic diseases like infectious diseases, oncology, cardiovascular disorders, rising healthcare expenditures, collaborations, mergers, and acquisitions.New York, May 06, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pharmaceutical Contract Manufacturing Global Market – Forecast To 2027" - https://www.reportlinker.com/p06070082/?utm_source=GNW Pharmaceutical companies are increasing their dependence on contract manufacturing organizations due to lack of well-equipped manufacturing facilities, advanced technologies, high containment capabilities or though they have the facilities, due to insufficient time and to have backup manufacturing, pharmaceutical companies are outsourcing. This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market. Contract pharmaceutical manufacturing services are mainly focused on the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).The pharmaceutical contract manufacturing global market is expected to reach $120,124.7 million by 2027 growing at a high single digit CAGR. Increased trend of outsourcing, high uptake of small molecules drugs across diverse therapeutics, patent expiration of small molecules, advanced technologies in API and FDF manufacturing, increasing deals and investments, increased demand for generic injectables, increasing incidence and prevalence of chronic diseases, and increase in geriatric population are some of the factors driving the market growth. However, contamination of pharmaceutical products (API and FDF), pricing pressure for pharmaceutical contract manufacturing, requirement of highly skilled technicians, increasing biologics approvals and adoption in disease management, stringent regulatory policies, and environmental concerns are some of the factors that are hindering pharmaceutical contract manufacturing global market growth. The pharmaceutical contract manufacturing global market is mainly segmented based on product, phase, application, and geography.The pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing segment accounted for the largest share in 2020 and FDF manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027. The high profit margin for pharma contract manufacturers, shifting from API to FDF manufacturing by CMOs and CDMOs, rising demand for advanced dosage forms, and rising demand for generic drugs are some of the factors driving the growth of the FDF contract manufacturing market.The API manufacturing market global market based on customer base is sub-segmented into Branded API manufacturing and Generic API manufacturing. The generic API manufacturing segment accounted for the largest revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027, due to the patent expiries of branded drugs, low cost of generic medicines.The FDF manufacturing global market based on dosage form is further classified into solid dosage form, injectable dosage form, and semi-solid liquid and gaseous dosage form. Solid dosage form segment accounted for the largest revenue in 2020 due to changing consumer demands, advent and progress of newer dosage forms, and ever-evolving regulations. The injectable dosage form is the fastest-growing segment and is expected to grow at a low teen CAGR from 2020 to 2027 due to its direct infusion to the body, ease of administration, and onset of action of drugs is faster as compared to solid dosage forms. Hence it is suitable for emergency conditions. Among semi-solid, liquid, and gaseous dosage form, semisolids segment accounted for the largest revenue of in 2020 owing to the increased usage of semisolids such creams, lotions and gels due to increase in skin related diseases, and changing climatic conditions.The solid dosage form market is further classified into tablets, capsules, and others such as powders and granules. Among these, tablets segment generated the largest revenue in 2020 owing to its ease of formulation techniques, manufacturing, and ease of administration to all the age groups.Pharmaceutical contract manufacturing global market based on phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing segment contributed to the largest revenue in 2020 due to huge demand for commercial API production, patent expiry, and increasing outsourcing of generic APIs. Whereas, clinical manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027 owing to a rise in demand for effective novel drugs with various therapeutic applications, rise in R&D investments for discovering new drugs coupled with the rising number of different types of chronic diseases.The pharmaceutical contract manufacturing market by therapeutic applications is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. Among these applications, the infectious disease segment accounted for the largest revenue in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is the fastest growing and is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs, increase in the usage of synthetic HPAPIs for cancer treatment, increase in geriatric population and rising demand for personalized medicine especially for treating cancer.The pharmaceutical contract manufacturing market based on region is classified into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others), and the Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue in 2020. The developed healthcare sector, availability of funds, increasing clinical trials, rising burden of cancer, increasing governments focus on generic drugs as well as the establishment of domestic API manufacturers, rising demands for the specialty of drugs and technological advancements, rising demand for advanced dosage forms, and also establishment of foreign CMOs/CDMOs are some of the factors driving the market growth. The Asia-Pacific region is the fastest growing region and is expected to grow at double digit CAGR from 2020 to 2027. Low labor cost, regulatory relaxation, abundance availability of raw materials, infrastructure facility, rise in generic demands, increased production capabilities, the presence of a large number of domestic and international players, coupled with low investments for the establishment of manufacturing facilities as compared to western countries.Some of the major players are Lonza Group (Switzerland), AbbVie Inc. (AbbVie contract manufacturing, U.S.), Thermo Fisher Scientific (Patheon, N.V., U.S.), Pfizer Inc. (Pfizer CentreOne, U.S.), Permira Funds (Cambrex Corporation, U.K.), Carlyle Group (Albany Molecular Research Inc. U.S.), WuXi AppTec (WuXi STA pharmaceuticals, China), Recipharm AB (publ) (Sweden), Aenova Group GmbH (Germany), China Resources Pharmaceutical Group Limited (China), and others.The report provides an in-depth market analysis of the above-mentioned segments across the following regions:• North Americao U.S.o Rest of North America• Europeo Germanyo Franceo Italyo Rest of Europe• Asia-Pacifico Chinao Indiao Japano Rest of APAC• Rest of the World (RoW)o Brazilo Rest of Latin Americao Middle East and OthersRead the full report: https://www.reportlinker.com/p06070082/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Learn why organic products are more expensive than regular products, and should you make the change?